Abstract

A new BLSA study of Prostate Growth and Disease was begun in February 1993 to examine anatomic and physiologic correlates of normal prostate growth and the development and progression of benign prostatic hyperplasia (BPH) and prostate cancer. In the past year, three studies have been completed. The first BLSA study developed age-specific reference ranges for prostate-specific antigen velocity (rate of change) and compared the sensitivity and specificity of different prostate-specific antigen (PSA) criteria for the detection of prostate cancer. In order to determine the optimal PSA testing regimen, the second study examined the variability in PSA levels in men with BPH and prostate cancer when measured at different time intervals. This study showed that PSA measurements obtained at 3 month or 6 month intervals are unlikely to be clinically useful. The third study developed age-specific norms for serum androgen levels in men (see Project Z01 AG 0013-20 LCP). These norms will be used to examine the relationship between age-adjusted androgen levels and risk of BPH or prostate cancer.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Intramural Research (Z01)
Project #
1Z01AG000633-06
Application #
5200333
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
1995
Total Cost
Indirect Cost

  Institution

Name
National Institute on Aging
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Loeb, Stacy; Kettermann, Anna; Ferrucci, Luigi et al. (2008) The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease. Eur Urol 54:978-979
Carter, H Ballentine; Kettermann, Anna; Ferrucci, Luigi et al. (2007) Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 70:685-90
Carter, H Ballentine; Kettermann, Anna; Warlick, Christopher et al. (2007) Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 178:2359-64;discussion 2364-5
Maggio, Marcello; Blackford, Amanda; Taub, Dennis et al. (2006) Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. J Androl 27:725-8
Carter, H Ballentine; Ferrucci, Luigi; Kettermann, Anna et al. (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98:1521-7
Parsons, J Kellogg; Carter, H Ballentine; Partin, Alan W et al. (2006) Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91:2562-8
Parsons, J Kellogg; Carter, H Ballentine; Platz, Elizabeth A et al. (2005) Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 14:2257-60
Platz, Elizabeth A; Rohrmann, Sabine; Pearson, Jay D et al. (2005) Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 14:390-6
Berndt, Sonja I; Carter, H Ballentine; Landis, Patricia K et al. (2005) Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer. Nutrition 21:686-90
Carter, H Ballentine; Landis, Patricia; Wright, E James et al. (2005) Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life? J Urol 173:2040-3

Showing the most recent 10 out of 21 publications